Sulfadiazine sodium is one of the short acting sulfonamide used in combinations with pyrimethamine. It is used in treating toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. It is used for prevention of recurrent attacks of rheumatic fever, urinary tract infections, and chlamydial infections in humans. Sulfadiazine sodium injections are also used in veterinary animals such as cattles to manage respiratory tract infections, genitourinary infections, alimentary tract infections, and sepsis.

Sulfadiazine Sodium Injection Market– Drivers

Rising awareness for safe antibiotic uses due to widespread antibiotic resistance can drive high demand for sulfadiazine sodium injection in the global market during the forecast period. For instance, World Antibiotic Awareness Week (WAAW) observed every year in the month of November, purposes to increase global awareness of antibiotic resistance (AMR) and encourage best practices among public, health workers, and policy makers to avoid emergence and spread of antibiotic resistance.

Furthermore, the mission of Alliance for the Prudent Use of Antibiotics (APUA) started in 1981, is working to strengthen global defenses against infectious diseases by ensuring access to effective antibiotics treatment and promoting appropriate antibiotic use to reduce drug resistance. By 2018, APUA is working in 19 countries and stands as the world’s leading organization conducting research and education on antimicrobial treatment and resistance at the grassroots and global levels.

Sulfadiazine Sodium Injection Market– Restraint

Over the years, bacterial pathogens acquired resistance to sulfonamide class of antibiotics, due to mutations in pre-existing DNA, or by acquisition of antibiotic resistance genes (ARGs), which is expected to hinder growth of the sulfachloropyridazine sodium market. For instance, according to Centers for Disease Control and Prevention (CDC), in the U.S. doctors and emergency departments, prescribe at least 47 million antibiotic prescriptions each year, which are unnecessary. These are creating spread of antibiotics resistance, which might lead to severe consequences.

Sulfadiazine Sodium Injection Market– Regional Analysis

On the basis of region, the global sulfadiazine sodium injection market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is estimated to hold the leading position in sulfadiazine sodium injection market due to rising use of antibiotics. For instance, according to the U.S. Food and Drug Administration (USFDA) 2015, about 9.7 million kilograms (21.4 million pounds) of antibiotics considered important for human use were sold for use in animal agriculture.

Europe is also expected to witness significant growth in the global sulfadiazine sodium injection market, owing to rising awareness of antibiotics resistance and safe and effective practice of antibiotics use in the region. For instance, the European Antibiotic Awareness Day is celebrated on 18 November every year. On November 16, 2018, the symposium for the 11th European Antibiotic Awareness Day was hosted by the Federal Ministry for Labour, Social Affairs, Health and Consumer Protection in cooperation with the Austrian national reference centre. The agenda for the symposium focused on raising awareness about importance of prudent antibiotic use.

Sulfadiazine Sodium Injection Market– Competitive Analysis

Key players operating in the global sulfadiazine sodium injection market include, AdvaCare Pharma, Mercator Pharma, Shijiazhuang ZDHF Stock-Raising Co., Ltd, Pegasus Laboratories, Inc., Weifang Fubang Pharmaceutical Co., Ltd., Hebei Tianyuan Pharmaceutical Co., Ltd., Hebei Veyong Animal Pharmaceutical Co., Ltd., and GENERA d.d.

Sulfadiazine Sodium Injection Market– Taxonomy

By Product Type